| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18255800P | 2000-02-15 | 2000-02-15 | |
| US60182558 | 2000-02-15 | ||
| US21150800P | 2000-06-14 | 2000-06-14 | |
| US60211508 | 2000-06-14 | ||
| PCT/US2001/004925WO2001060412A2 (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
| Publication Number | Publication Date |
|---|---|
| AU2001238346A1true AU2001238346A1 (en) | 2001-08-27 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001238346AAbandonedAU2001238346A1 (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
| Country | Link |
|---|---|
| EP (1) | EP1263472A2 (en) |
| JP (1) | JP2003522806A (en) |
| AU (1) | AU2001238346A1 (en) |
| CA (1) | CA2400205A1 (en) |
| IL (1) | IL151024A0 (en) |
| WO (1) | WO2001060412A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1630720A (en)* | 2001-01-18 | 2005-06-22 | 默克专利有限公司 | Bifunctional fusion proteins with glucocerebrosidase activity |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| WO2004060404A1 (en)* | 2002-12-27 | 2004-07-22 | Chugai Seiyaku Kabushiki Kaisha | Drug carrier |
| AU2004252091B2 (en)* | 2003-06-05 | 2010-06-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
| EP1643958A4 (en)* | 2003-06-18 | 2010-09-01 | Nst Neurosurvival Technologies | Method for selective targeting of apoptotic cells and small molecule ligands used thereof |
| WO2005037144A2 (en)* | 2003-10-10 | 2005-04-28 | Cellular Bioengineering, Inc. | Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants |
| US7625736B2 (en) | 2004-06-04 | 2009-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for preparing immunogenic conjugates |
| TW200612991A (en) | 2004-09-07 | 2006-05-01 | Chugai Pharmaceutical Co Ltd | Process for producing water-soluble hyaluronic acid modification |
| JP5137814B2 (en)* | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | Conjugation of PEG and polysialicosomal enzymes via acid labile linkers for therapeutic targeting |
| WO2007008904A2 (en) | 2005-07-08 | 2007-01-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections |
| PT2457920T (en) | 2007-01-18 | 2018-01-23 | Genzyme Corp | Oligosaccharides comprising an aminooxy group and conjugates thereof |
| JP5658167B2 (en) | 2008-12-16 | 2015-01-21 | ジェンザイム・コーポレーション | Oligosaccharide-protein complex |
| US9243077B2 (en) | 2011-03-03 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Derivative of hyaluronic acid modified with amino-carboxylic acid |
| WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
| CN104603156B (en) | 2012-09-05 | 2016-10-26 | 中外制药株式会社 | Introduce and have aminoacid and the derivatives of hyaluronic acids of steroid base |
| KR102049568B1 (en)* | 2013-04-01 | 2019-11-27 | 삼성전자주식회사 | Composition for nucleic acid delivery containing hyaluronic acid |
| GB201602359D0 (en)* | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN108440684A (en)* | 2018-03-22 | 2018-08-24 | 华侨大学 | A kind of NI-Cys-Alg self-assembled nanometers carrier and its preparation method and application |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05505941A (en)* | 1990-03-29 | 1993-09-02 | ギリード サイエンシズ インコーポレーテッド | Oligonucleotide-transport agent disulfide conjugate |
| US5169934A (en)* | 1990-05-14 | 1992-12-08 | Anergen, Inc. | Intracellularly cleavable compounds |
| US6335434B1 (en)* | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| ATE168014T1 (en)* | 1991-11-08 | 1998-07-15 | Somatogen Inc | HEMOGLOBINS AS A DRUG DELIVERY SYSTEM |
| US5902795A (en) | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
| US5329029A (en) | 1992-11-05 | 1994-07-12 | Wan Barbara Y | Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates |
| AU673057B2 (en)* | 1993-02-22 | 1996-10-24 | Abraxis Bioscience, Llc | Methods for (in vivo) delivery of biologics and compositionsuseful therefor |
| US5354853A (en) | 1993-03-12 | 1994-10-11 | Genzyme Corporation | Phospholipid-saccharide conjugates |
| AU734827B2 (en)* | 1997-05-21 | 2001-06-21 | Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| US5932552A (en) | 1997-11-26 | 1999-08-03 | Keraplast Technologies Ltd. | Keratin-based hydrogel for biomedical applications and method of production |
| Publication number | Publication date |
|---|---|
| JP2003522806A (en) | 2003-07-29 |
| EP1263472A2 (en) | 2002-12-11 |
| CA2400205A1 (en) | 2001-08-23 |
| IL151024A0 (en) | 2003-02-12 |
| WO2001060412A3 (en) | 2002-01-24 |
| WO2001060412A2 (en) | 2001-08-23 |
| Publication | Publication Date | Title |
|---|---|---|
| AU2001235009A1 (en) | Drug delivery apparatus | |
| AU2001269529A1 (en) | Medicine comprising dicyanopyridine derivative | |
| AU2001264887A1 (en) | Drug delivery device | |
| AU2001288388A1 (en) | Substance delivery system | |
| EP1455697A4 (en) | Vaginal delivery of drugs | |
| AU2002217979A1 (en) | Medicine feeder | |
| AU2001235691A1 (en) | Use of paullone derivatives for making medicines | |
| AU2001238346A1 (en) | Modification of biopolymers for improved drug delivery | |
| AU2002343555A1 (en) | Eutectic-based self-nanoemulsified drug delivery system | |
| AU2001276860A1 (en) | Medicaments for chemotherapeutic treatment of disease | |
| AU2002353444A1 (en) | Integrated transdermal drug delivery system | |
| AUPR573001A0 (en) | Lymphatic drug delivery system | |
| AU2001277171A1 (en) | Catheter for target specific drug delivery | |
| AU6887401A (en) | Delivery of remotely-ordered products | |
| AU2001270778A1 (en) | Production, stabilisation and use of reduced forms of pharmaceutical compounds | |
| AU2001232020A1 (en) | Floating drug delivery composition | |
| AU777185C (en) | Pharmaceutical form of administration for peptides, methods for its production and use | |
| AU2002360717A1 (en) | Controlled release dosage form having improved drug release properties | |
| AU2001270963A1 (en) | Transdermal drug delivery system | |
| AU2001232244A1 (en) | Drug comprising combination | |
| AU2002308649A1 (en) | Compositions and methods for enhancing drug delivery | |
| AU2001260089A1 (en) | Pharmaceutical compositions comprising desglymidodrine as an active drug substance | |
| AU3926000A (en) | Methods and compositions for drug delivery | |
| AU2002222138A1 (en) | Drug delivery system | |
| AU2002212863A1 (en) | Stable pharmaceutical form of an anticancer drug |